A multicenter study led by researchers from the State Key Laboratory of Ophthalmology in China has characterized a distinct ...

A one-time injection of Lumevoq demonstrated sustained visual acuity improvements with a favorable safety profile at 5 years ...

The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with diabetic macular edema (DME) who have previously responded to at least 2 ...

At a mean of 16.1 days after fever onset, patients experienced initial symptoms including sudden vision loss, visual field ...

Company shares preliminary results from Phase 1/2 clinical trial for patients with advanced Retinitis Pigmentosa (RP)NEW YORK, Feb. 18, 2025 ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.

D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential. Click here to find out why I rate ...

COAST Phase 3 trial evaluates superiority and safety of sozinibercept combined with aflibercept in wet AMDCompany confirms topline results for ...

Rural Medevac Alliance announced that its local base of operations, Battle Born Medevac 1, is now operational 24/7. Over the ...

So far, five biosimilars that reference Eylea 2 mg have been approved by the FDA. Alvotech/Teva expect to regulatory approval for its biosimilar to be completed in the fourth quarter of 2025.

At the Envision Summit 2025 in San Juan, Puerto Rico, Deepak Sambhara, MD, gave insight into the 96-week post hoc fluid ...

The first of Opthea’s (ASX:OPT) two phase III eye disease trials has hit a key development milestone, with the last patient ...